Among men whose low-risk prostate cancer was managed with so-called active surveillance for up to 15 years, just 1.5 percent died of the cancer, according to new data from a Canadian study. That result is similar to outcomes in men whose cancers are treated immediately, the authors write. Read the article from Scientific American.
“Surveillance” May Be Safest for Low-Risk Prostate Cancer Read More »
In the article accompanying this editorial, Klotz et al report the longest follow-up to date in one of the largest extant active surveillance cohorts. Read this article.
Long-Term Active Surveillance for Prostate Cancer: Answers and Questions Read More »
The year 2014 has again provided important developments in the area of prostate cancer. New data and new treatments span the spectrum of prostate cancer management, from prevention and screening to optimal strategies for localized, locally advanced, and metastatic disease. Read the article. (Free Medscape account required.)
Advances in Prostate Cancer: 2014 Read More »
The challenge in prostate cancer (PCa) is to match the aggressiveness of the treatment to that of the cancer. Until recently, all screen-diagnosed localized cancers were considered at least potentially aggressive and in most cases were treated radically. Active surveillance represented a major step forward in acknowledging that some cancers were clinically insignificant and did not pose a threat to the patient’s life. Recently, a third option—focal therapy—has emerged as a potential middle ground between radical treatment and active surveillance. Read the article.
Here are 2 articles on Gleason 6 Prostate Cancer: Gleason 6 Prostate Cancer: Serious Malignancy or Toothless Lion? – See More and a follow-up: Gleason 6 Cancer Is Still Cancer – See More
Gleason 6 Prostate Cancer: Serious Malignancy or Toothless Lion? Read More »
Researchers from Weill Cornell Medical College have shown that the presence of a particular protein in biopsied prostate tissue substantially increases the likelihood that cancer will develop in that organ. The discovery will likely help physicians decide how closely to monitor men potentially at risk for the cancer—among the most confusing and controversial dilemmas in health care. Read the article.
Protein in prostate biopsies signals increased cancer risk Read More »
A new test for prostate cancer could spare thousands of men needless treatment which leaves them with debilitating side effects, researchers claim. The test can accurately pinpoint the less harmful tumours which do not have to be immediately removed by surgery or radiotherapy. Read more: http://www.dailymail.co.uk/health/article-2487483/New-prostate-test-identifies-harmful-tumours-need-removed-immediately-spare-men-needless-surgery.html#ixzz2lIfSTsd7
This is one of Dr. Myers’ regular videos. To view it and related videos, click here.
Avodart + Active Surveillance Read More »
Prostate cancer (PCa) patients who drink at least one cup of coffee per day may experience a significantly decreased risk of PCa recurrence or progression after treatment or while on active surveillance, researchers reported. Read the article.(Includes a brief video)
Coffee May Cut Risk of Prostate Cancer Recurrence, Progression Read More »
Now that the government panels and medical associations no longer recommend PSA testing, consider this: in the 1980s, before PSA testing, 50,000 men died annually from prostate cancer. In the 1990s, with PSA testing, 30,000 died annually. PSA testing saved 20,000 men each year (about 25,000 now) from slow, painful deaths from prostate cancer. And they are telling us to stop doing this test? Consider: 50,000 prostatectomies are performed each year for prostate cancer, yet 40,000 of these surgeries are unnecessary. The numbers are similar for radiation therapy. This is why mainstream medicine has retreated from routine PSA testing. Retreating
5 Ways to Prevent Unnecessary Treatment for Prostate Cancer Read More »